SYRE Stock Summary and Trading Ideas (Spyre Therapeutics | NASDAQ:SYRE)

Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.

Spyre Therapeutics trades on the NASDAQ stock market under the symbol SYRE.

As of April 4, 2025, SYRE stock price declined to $12.79 with 1,614,735 million shares trading.

SYRE has a beta of 1.94, meaning it tends to be more sensitive to market movements. SYRE has a correlation of 0.16 to the broad based SPY ETF.

SYRE has a market cap of $771.24 million. This is considered a Small Cap stock.

Last quarter Spyre Therapeutics reported $0 in Revenue and -$.81 earnings per share. This fell short of revenue expectation by $-2 million and exceeded earnings estimates by $.16.

The top ETF exchange traded funds that SYRE belongs to (by Net Assets): VTI, VXF, IWM, XBI, IWN.

SYRE has underperformed the market in the last year with a price return of -63.1% while the SPY ETF lost -1.3%. SYRE has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.5% and -29.5%, respectively, while the SPY returned -14.4% and -10.1%, respectively.

SYRE support price is $13.27 and resistance is $14.71 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYRE shares will trade within this expected range on the day.